This is after youve tried exercise, nutrition, then you can use this in addition. CORRECTION (Feb
You can read more about it in this report from the California Medical Association
For type 2 diabetes , NICE guideline NG28 recommends considering GLP-1 agonists as an option when: Triple therapy with metformin and two other oral drugs is ineffective, not tolerated, or contraindicated The person has a BMI 35 kg/m (or 32.5 kg/m in people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity Insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities Treatment should be continued only if there is a beneficial metabolic response (HbA1c reduction of at least 11 mmol/mol [1.0%] and weight loss of at least 3% of initial body weight at 6 months)
Angry patients spur new state watchdogs to bring down drug prices But one researcher, John Cawley, a professor of economics and public policy at Cornell University, and his colleagues found that while obesity basically doubles a persons annual health care costs, the savings associated with public insurance plans covering GLP-1s for just obesity treatment are dependent on the patients starting body mass index, or BMI
With the coming explosion of obesity drugs, doctors could soon match each patients condition to their optimal medication: A 25-year-old with fatty-liver disease may need a different drug than a 75-year-old with low muscle mass
